D. A. Yardley, “NCT00789581 (Titan) Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone Vs AC Followed by Paclitaxel in Patients with Triple-Negative Early-Stage Breast Cancer,” 2011. http://clinicaltrials.gov

has been cited by the following article:

• TITLE: Triple Negative Breast Cancer Treatment: Use of Platinum and Platinum Analogs

  AUTHORS: Manuela Fantini, Carlotta Santelmo, Fabrizio Drudi, Claudio Ridolfi, Eleonora Barzotti, Lorenzo Gianni, Valentina Arcangeli, Alessandra Affatato, Alberto Ravaioli

  KEYWORDS: Breast Cancer; Triple Negative; Treatment; Platinum; Platinum Analogs

  JOURNAL NAME: Journal of Cancer Therapy, Vol.3 No.5A, November 1, 2012

  ABSTRACT: Triple negative breast cancer (TNBC) is characterized by a high sensitivity to antiblastic drugs and a high pathological complete remission rate after neoadjuvant therapy. In patients showing complete remission, the probability of developing metastatic disease would seem to be reduced. Nonetheless, this cancer has a high percentage of relapse. Anthracyclines, taxanes and platinum compounds are the most effective drugs for the treatment of TNBC. There is substantial evidence to support the efficacy of platinum-based chemotherapy, probably attributable to the mechanism of action of such drugs, which react with the DNA repair system. PARP inhibitors would also seem to be very interesting. Despite promising results, TNBC remains a disease with a poor prognosis due to the lack of targeted therapy. The discovery of new targets and new agents is thus a high priority issue for this type of breast cancer. In this respect, lipoplatin has been identified as a potentially interesting treatment option to evaluate in both neoadjuvant and advanced settings.